This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalafatis, M. Articles by Mann, K. G. Search for Related Content PubMed PubMed Citation Articles by Kalafatis, M. Articles by Mann, K. G.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:620-627.)
© 1997 American Heart Association, Inc.

Articles

Factor V^Leiden and Thrombophilia

Michael Kalafatis; ; Kenneth G. Mann

From the Department of Biochemistry, University of Vermont College of Medicine, Burlington.

Correspondence to Kenneth G. Mann, PhD, Department of Biochemistry, Given Building, Health Science Complex, University of Vermont College of Medicine, Burlington, VT 05405-0068.

Key Words: activated protein C • venous thrombosis • activated protein C resistance • factor V^Leiden • thrombophilia

	Introduction

 
Blood coagulation is initiated after injury to the vasculature and exposure of TF. TF is an integral single-chain glycoprotein that, when exposed to the circulating blood, binds to circulating factor VIIa and initiates the process of blood coagulation. Although the majority of factor VII molecules circulate in plasma as a single-chain, inactive zymogen, 2% of them possess a Ser protease active site but have poor catalytic activity.^{1 2} After binding to TF, the catalytic efficiency of the factor VIIa/TF complex increases by four orders of magnitude, and the enzymatic complex initiates a series of enzymatic reactions that lead to the generation of -thrombin.^{2 3} The prothrombin-activating enzyme prothrombinase is composed of the Ser protease factor Xa and cofactor factor Va, associated on the cell membrane.⁴ Factor Va is required for prothrombinase activity because it serves the dual function as a factor Xa receptor and a factor Xa catalytic effector on the cell surface. Both enzyme and cofactor are derived from plasma precursors by regulatory proteolytic events that involve -thrombin. These events include activation of factor VIII to factor VIIIa and of factor V to factor Va. -Thrombin, the major procoagulant enzyme of the blood coagulation cascade, is also paradoxically a major anticoagulant. Once formed, -thrombin binds to the endothelial cell receptor thrombomodulin and initiates the protein C pathway that leads to the formation of APC. The protein C pathway is composed of the zymogen protein C, thrombomodulin, and the accessory protein, protein S.⁵ APC downregulates -thrombin generation by inactivating factors Va and . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Toso and R. M. Camire Removal of B-domain Sequences from Factor V Rather than Specific Proteolysis Underlies the Mechanism by Which Cofactor Function Is Realized J. Biol. Chem., May 14, 2004; 279(20): 21643 - 21650. [Abstract] [Full Text] [PDF]

				M. Kalafatis, P. Simioni, D. Tormene, D. O. Beck, S. Luni, and A. Girolami Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations Blood, May 13, 2002; 99(11): 3985 - 3992. [Abstract] [Full Text] [PDF]

				N. Akar, E. Akar, E. Yilmaz, and G. Deda Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Children With Cerebral Infarct and Effect on Factor V 1691 A Mutation J Child Neurol, April 1, 2001; 16(4): 294 - 295. [Abstract] [PDF]

				E. Castoldi, P. Simioni, M. Kalafatis, B. Lunghi, D. Tormene, D. Girelli, A. Girolami, and F. Bernardi Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family Blood, August 15, 2000; 96(4): 1443 - 1448. [Abstract] [Full Text] [PDF]

				A. J. Gale, M. J. Heeb, and J. H. Griffin The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites Blood, July 15, 2000; 96(2): 585 - 593. [Abstract] [Full Text] [PDF]

				D. A. Lane and P. J. Grant Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease Blood, March 1, 2000; 95(5): 1517 - 1532. [Full Text] [PDF]

				S. Cheng, M. A. Grow, C. Pallaud, W. Klitz, H. A. Erlich, S. Visvikis, J. J. Chen, C. R. Pullinger, M. J. Malloy, G. Siest, et al. A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk Genome Res., October 1, 1999; 9(10): 936 - 949. [Abstract] [Full Text]

				M. Kalafatis, F. Bernardi, P. Simioni, B. Lunghi, A. Girolami, and K. G. Mann Phenotype and Genotype Expression in Pseudohomozygous Factor VLEIDEN : The Need for Phenotype Analysis Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 336 - 342. [Abstract] [Full Text] [PDF]

				R. M. Camire, E. S. Pollak, K. Kaushansky, and P. B. Tracy Secretable Human Platelet-Derived Factor V Originates From the Plasma Pool Blood, November 1, 1998; 92(9): 3035 - 3041. [Abstract] [Full Text] [PDF]

				R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C Blood, April 15, 1998; 91(8): 2818 - 2829. [Abstract] [Full Text] [PDF]

				M. F. Hockin, M. Kalafatis, M. Shatos, and K. G. Mann Protein C Activation and Factor Va Inactivation on Human Umbilical Vein Endothelial Cells Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2765 - 2775. [Abstract] [Full Text]